Stock VNDA VANDA PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Share ownership Vanda Pharmaceuticals Inc.

Equities

VNDA

US9216591084

Biotechnology & Medical Research

Real-time Estimate Cboe BZX
Other stock markets
 17:47:34 17/09/2024 BST 		5-day change 1st Jan Change
4.950 USD -2.56% Intraday chart for Vanda Pharmaceuticals Inc. -0.52% +17.39%
07-31 Transcript : Vanda Pharmaceuticals Inc., Q2 2024 Earnings Call, Jul 31, 2024
07-31 Earnings Flash (VNDA) VANDA PHARMACEUTICALS Reports Q2 Revenue $50.5M, vs. Street Est of $47.9M MT

Share class: Vanda Pharmaceuticals Inc.

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A158,289,80856,447,619 ( 96.84 %) 0 96.84 %

Major shareholders: Vanda Pharmaceuticals Inc.

NameEquities%Valuation
BlackRock Advisors LLC
12.68 %
7,394,027 12.68 % 39 M $
Renaissance Technologies LLC
7.058 %
4,114,125 7.058 % 22 M $
Vanguard Fiduciary Trust Co.
5.887 %
3,431,671 5.887 % 18 M $
Tang Capital Management LLC
3.694 %
2,153,307 3.694 % 11 M $
Acadian Asset Management LLC
3.400 %
1,982,027 3.400 % 10 M $
DFA Australia Ltd.
3.296 %
1,921,073 3.296 % 10 M $
Mihael Polymeropoulos
3.211 %
1,871,730 3.211 % 10 M $
Nantahala Capital Management LLC
2.734 %
1,593,516 2.734 % 8 M $
Jacobs Levy Equity Management, Inc.
2.550 %
1,486,262 2.550 % 8 M $
Geode Capital Management LLC
2.283 %
1,330,957 2.283 % 7 M $
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░
░░░░░░░░░░░░░░░░░░░░░░░░░ ░ ░░░ ░░░░% ░░

Breakdown by shareholder type

Institutional64.90%
Other7.60%
Individuals5.31%
State Street Corp.2.08%
SEI Investments Co.0.68%
Corebridge Financial, Inc.0.05%
Manulife Financial Corp.0.04%
Banque Cantonale Vaudoise0.02%
Unknown19.32%

Based on 1000 largest holdings

Geographical origin of shareholders

United States 65.70%
Individuals 5.31%
Australia 3.30%
United Kingdom 2.48%
Canada 1.57%
Ireland 1.09%
Norway 0.43%
Germany 0.35%
Monaco 0.33%
Switzerland 0.03%
Cayman Islands 0.02%
Spain 0.02%
New Zealand 0.02%
Hong Kong 0.02%
China 0.01%

Based on 1000 largest holdings

Company Profile

Logo Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in smith-magenis syndrome (SMS), Fanapt (iloperidone) for the treatment of bipolar I disorder and a long acting injectable (LAI) formulation for the treatment of schizophrenia, and PONVORY (ponesimod) for the treatment of inflammatory/autoimmune disorders, including ulcerative colitis, psoriasis, Crohn's disease, atopic dermatitis, eosinophilic esophagitis and alopecia areata. The Company also has a range of drugs in development, including Tradipitant (VLY-686), VHX-896, VSJ-110, VPO-227, VTR-297, VQW-765, VCA-894A and Type 2S (CMT2S).
Employees
203
Sector
Biotechnology & Medical Research
Calendar
19/09/2024 - Cantor Global Healthcare Conference
More about the company
  1. Stock Market
  2. Equities
  3. VNDA Stock
  4. Company Vanda Pharmaceuticals Inc.
  5. Share ownership
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition